Drugs in tuberculosis and leprosy

Meenakshi R. Ramanathan, Crystal K. Howell, James M. Sanders

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations


Tuberculosis (TB) remains a global health threat with approximately 25% of the world's population infected with latent tuberculosis infection (LTBI). Approximately 10% of these patients will develop active TB. Both TB and leprosy are known for their infectious and contagious nature and with increasing resistance patterns emerging and treatment regimens requiring a combination of products (with variable toxicity profiles, drug–drug interactions, and treatment outcomes) to combat the resistance. In this chapter, we review the 2018 literature regarding the adverse effects of medications commonly used in TB and leprosy: aminoglycosides, bedaquiline, carbapenems, clofazimine, cycloserine, dapsone, ethambutol, fluoroquinolones, isoniazid, linezolid, macrolides, pyrazinamide, para-aminosalicylic acid, polypeptides, rifamycins, terizidone, and thiacetazone.

Original languageEnglish (US)
Title of host publicationA Worldwide Yearly Survey of New Data in Adverse Drug Reactions
EditorsSidhartha D. Ray
PublisherElsevier B.V.
Number of pages18
ISBN (Print)9780128171639
StatePublished - 2019

Publication series

NameSide Effects of Drugs Annual
ISSN (Print)0378-6080


  • Adverse effects
  • Ethambutol
  • Isoniazid
  • Leprosy
  • Pyrazinamide
  • Rifamycins
  • Side effect
  • Tuberculosis

ASJC Scopus subject areas

  • Pharmacology
  • Drug guides
  • Pharmacology (medical)


Dive into the research topics of 'Drugs in tuberculosis and leprosy'. Together they form a unique fingerprint.

Cite this